{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:24:16Z","timestamp":1772515456918,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100014069","name":"Champalimaud Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014069","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01314-7","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:35:46Z","timestamp":1766140546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glioblastoma zebrafish Avatars guide therapeutic decisions in a patient with gliosarcoma: a case report"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5397-2550","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Fontes","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0684-7347","authenticated-orcid":false,"given":"Daniela","family":"Garcez","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Ruivo","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Albuquerque","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Viegas","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"da Cruz-Ribeiro","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Lima","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Mafra","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Bravo","family":"Marques","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5550-2428","authenticated-orcid":false,"given":"Rita","family":"Fior","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"1314_CR1","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen, P. Y. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncol. 22, 1073\u20131113 (2020).","journal-title":"Neuro-Oncol."},{"key":"1314_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2011.06.014","volume":"146","author":"C Liu","year":"2011","unstructured":"Liu, C. et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146, 209\u2013221 (2011).","journal-title":"Cell"},{"key":"1314_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrc2818","volume":"10","author":"JT Huse","year":"2010","unstructured":"Huse, J. T. & Holland, E. C. Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10, 319\u2013331 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"1314_CR4","doi-asserted-by":"crossref","unstructured":"Weller, M., Rhun, E. L., & Roth, P. How we treat glioblastoma. ESMO Open Cancer Horizons 17, 520 (2019)","DOI":"10.1136\/esmoopen-2019-000520"},{"key":"1314_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1314_CR6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen, M. H., Shen, Y. L., Keegan, P. & Pazdur, R. FDA drug approval summary: bevacizumab (Avastin\u00ae) as treatment of recurrent glioblastoma multiforme.  Oncologist 14, 1131\u20131138 (2009).","journal-title":"Oncologist"},{"key":"1314_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot, O. L. et al. Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709\u2013722 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1314_CR8","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3390\/cancers15072116","volume":"15","author":"SSK Yalamarty","year":"2023","unstructured":"Yalamarty, S. S. K. et al. Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM). Cancers 15, 2116 (2023).","journal-title":"Cancers"},{"key":"1314_CR9","doi-asserted-by":"crossref","unstructured":"Costa, B. et al. Developments in zebrafish avatars as radiotherapy sensitivity reporters \u2014 towards personalized medicine. EBioMedicine 51, 1\u201312 (2020)","DOI":"10.1016\/j.ebiom.2019.11.039"},{"key":"1314_CR10","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston, D. R. & Davis, M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin. Cancer Res 23, 3489\u20133498 (2017).","journal-title":"Clin. Cancer Res"},{"key":"1314_CR11","doi-asserted-by":"publisher","unstructured":"Martinez-lopez, M., P\u00f3voa, V., & Fior, R. Generation of Zebrafish Larval Xenografts and Tumor Behavior Analysis. Jove, June. https:\/\/doi.org\/10.3791\/62373 (2021).","DOI":"10.3791\/62373"},{"key":"1314_CR12","doi-asserted-by":"publisher","unstructured":"Fior, R. et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. PNAS. https:\/\/doi.org\/10.1073\/pnas.1618389114 (2017).","DOI":"10.1073\/pnas.1618389114"},{"key":"1314_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"1314_CR14","doi-asserted-by":"crossref","unstructured":"Alhalabi, O. et al. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat. Commun. 13, 1\u201312 (2022).","DOI":"10.1038\/s41467-022-29397-z"},{"key":"1314_CR15","doi-asserted-by":"publisher","first-page":"vdad162","DOI":"10.1093\/noajnl\/vdad162","volume":"6","author":"MP Castro","year":"2023","unstructured":"Castro, M. P. & Dittmar, K. Network targeting combination therapy of synthetic lethal vulnerabilities in 9p21-deficient glioblastoma: a case report. Neuro-Oncol. Adv. 6, vdad162 (2023).","journal-title":"Neuro-Oncol. Adv."},{"key":"1314_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.annonc.2024.09.009","volume":"35","author":"L Boscolo Bielo","year":"2024","unstructured":"Boscolo Bielo, L. & Curigliano, G. Synthetic lethality in MTAP-deleted tumors: a promising avenue through targeted disruption of the protein methylation pathway. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 35, 1080\u20131082 (2024).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"1314_CR17","doi-asserted-by":"publisher","first-page":"57337","DOI":"10.18632\/oncotarget.16924","volume":"8","author":"SB Yang","year":"2017","unstructured":"Yang, S. B., Gao, K. D., Jiang, T., Cheng, S. J. & Li, W. B. Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials. Oncotarget 8, 57337\u201357344 (2017).","journal-title":"Oncotarget"},{"key":"1314_CR18","doi-asserted-by":"publisher","first-page":"603947","DOI":"10.3389\/fneur.2020.603947","volume":"11","author":"X Ren","year":"2021","unstructured":"Ren, X., Ai, D., Li, T., Xia, L. & Sun, L. Effectiveness of lomustine combined with bevacizumab in glioblastoma: a meta-analysis. Front. Neurol. 11, 603947 (2021).","journal-title":"Front. Neurol."},{"key":"1314_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","volume":"23","author":"M Fu","year":"2023","unstructured":"Fu, M. et al. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC cancer 23, 544 (2023).","journal-title":"BMC cancer"},{"key":"1314_CR20","doi-asserted-by":"publisher","first-page":"12650","DOI":"10.21037\/apm-21-3382","volume":"10","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Combined carboplatin and etoposide chemotherapy for patients with recurrent glioma. Ann. Palliat. Med. 10, 12650\u201312656 (2021).","journal-title":"Ann. Palliat. Med."},{"key":"1314_CR21","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. Off. 27, 4733\u20134740 (2009).","journal-title":"J. Clin. Oncol. Off."},{"key":"1314_CR22","doi-asserted-by":"publisher","first-page":"1199292","DOI":"10.3389\/fphar.2023.1199292","volume":"14","author":"Z Tian","year":"2023","unstructured":"Tian, Z. & Yao, W. Chemotherapeutic drugs for soft tissue sarcomas: a review. Front. Pharmacol. 14, 1199292 (2023).","journal-title":"Front. Pharmacol."},{"key":"1314_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/cancers17050889","volume":"17","author":"A Paudel","year":"2025","unstructured":"Paudel, A. et al. Systemic treatment in soft tissue sarcomas: are we making a difference? Cancers 17, 889 (2025).","journal-title":"Cancers"},{"key":"1314_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/1758834017712963","volume":"9","author":"GK In","year":"2017","unstructured":"In, G. K., Hu, J. S. & Tseng, W. W. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Therapeutic Adv. Med. Oncol. 9, 533\u2013550 (2017).","journal-title":"Therapeutic Adv. Med. Oncol."},{"key":"1314_CR25","doi-asserted-by":"publisher","first-page":"e188120","DOI":"10.1172\/JCI188120","volume":"135","author":"X Zeng","year":"2025","unstructured":"Zeng, X. et al. Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop.  J. Clin. Investig. 135, e188120 (2025).","journal-title":"J. Clin. Investig."},{"key":"1314_CR26","doi-asserted-by":"crossref","unstructured":"De Almeida, C. R. et al. (n.d.). Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy. Commun. Biol. 3, 299 (2020).","DOI":"10.1038\/s42003-020-1015-0"},{"key":"1314_CR27","doi-asserted-by":"crossref","unstructured":"Costa, B. et al. Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer. Nat. Commun. 15, 4771 (2024).","DOI":"10.1038\/s41467-024-49051-0"},{"key":"1314_CR28","doi-asserted-by":"crossref","unstructured":"Mendes, R. V. Zebrafish Avatar-test predicts patient\u2019s tumor response to chemotherapy in breast cancer: a co-clinical study towards personalized medicine. npj Precis Oncol. 9, 94 (2024).","DOI":"10.1101\/2024.10.03.616349"},{"key":"1314_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11060-006-9295-x","volume":"83","author":"TL Beaumont","year":"2007","unstructured":"Beaumont, T. L., Kupsky, W. J., Barger, G. R. & Sloan, A. E. Gliosarcoma with multiple extracranial metastases: case report and review of the literature. J. neuro-Oncol. 83, 39\u201346 (2007).","journal-title":"J. neuro-Oncol."},{"key":"1314_CR30","doi-asserted-by":"publisher","first-page":"1553408","DOI":"10.1155\/2023\/1553408","volume":"2023","author":"Z Yu","year":"2023","unstructured":"Yu, Z. et al. Prognostic factors of gliosarcoma in the real world: a retrospective cohort study. Comput. Math. Methods Med. 2023, 1553408 (2023).","journal-title":"Comput. Math. Methods Med."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01314-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:45:10Z","timestamp":1769179510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01314-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1314"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01314-7","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}